Document 0027
 DOCN  M9610027
 TI    Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS.
 DT    9601
 AU    Vance E; Watson-Bitar M; Gustavson L; Kazanjian P; Department of
       Medicine, Brigham and Women's Hospital, Boston,; Massachusetts, USA.
 SO    Antimicrob Agents Chemother. 1995 Jun;39(6):1355-60. Unique Identifier :
       AIDSLINE MED/96012200
 AB    The interrelationships between the pharmacokinetics of zidovudine alone
       and of zidovudine plus clarithromycin were evaluated with 18 volunteers
       with AIDS who had no infection with Mycobacterium avium complex or
       clinical evidence of gastroenteritis. Patients received 200 mg of
       zidovudine orally every 8 h on days 1 to 4 and 1,000 mg of
       clarithromycin every 12 h, given 2 h apart from zidovudine, on days 2 to
       4. Concentrations of zidovudine in plasma were measured at steady state
       both prior to (phase 1, day 1) and during (phase 2, day 4)
       administration of clarithromycin. Levels of clarithromycin were measured
       at steady state on day 4. The maximum concentrations of zidovudine in
       plasma were significantly different in phases 1 and 2 (616.6 and 949.0
       ng/ml, respectively), as were the times to the maximum concentrations of
       zidovudine (2.1 and 1.0 h, respectively). However, the minimum
       concentrations in plasma and the areas under the concentration-time
       curves from 0 to 6 h did not differ on days 1 and 4. There is no
       significant impact on the overall bioavailability of zidovudine from the
       addition of clarithromycin in patients with AIDS. Clarithromycin may
       increase the rate of zidovudine absorption, but this is unlikely to have
       clinical relevance.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY/*METABOLISM  Adult
       Clarithromycin/ADMINISTRATION & DOSAGE/BLOOD/*PHARMACOKINETICS
       Comparative Study  Drug Therapy, Combination  Female  Human  Male
       Middle Age  Time Factors  Zidovudine/ADMINISTRATION &
       DOSAGE/BLOOD/*PHARMACOKINETICS  CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).